AdAlta and SYNthesis BioVentures Fund announced a partnership via a memorandum of understanding to establish AdCella, aimed at advancing cellular immunotherapy innovations from Asia to Western markets, focusing on treating solid cancers.

The collaboration will utilise AdAlta's i-body technology to improve the delivery and efficacy of therapies in Western clinical settings.

AdCella plans to capitalise on the biomedical landscape of the Asia Pacific region and Australia's clinical trial ecosystem to introduce novel cellular immunotherapies to Western markets.

The initiative could expedite access to therapies for Australian patients.